Notifications
Back

Vaxdigm Technology

CHAPERNOVA™ PLATFORM

Vaxdigm Technology

CHAPERNOVA™ PLATFORM

About Technology

ChaperNova™ is a protein engineering platform which solves the problem of insoluble aggregate formation

ChaperNova™ is a protein engineering platform based on RNA-protein interaction, addressing the main problem of microbe-based protein manufacturing processes: the formation of insoluble aggregates (Inclusion body).


Our technology removes aggregation by encouraging interaction with RNA during the initial steps of protein synthesis and aims to convert the proteins already expressed in an encapsulated form into their soluble form. Soluble expression improvement and functional constancy have been confirmed through various experiments, most significantly verifying RNA’s dependable combination ability, securing technological confidence.

Our Technology

ChaperNova™ takes a novel approach by guiding protein folding during early translation, rather than after full formation.

Our Mechanism

Vaxdigm presents a unique, highly-employable protein manufacturing technology based on ChaperNova™

All protein-based products (pharmaceuticals, cosmetics, materials) require an expression system: E.coli, yeast, mammalian cells.

Microbe-expression systems allow low-cost, high-speed production,

yet are limited by protein aggregates.

* M : Marker / Tot : Total protein / Sol : Soluble protein / Insol : Insoluble protein

mobile background

Our Technology ChaperNova™

Biomaterials with quicker productivity,

higher profitability, and improved effectivity.

Ablility to develop multiple pipelines based on the same platform




01

Reduced production costs of protein products

Compared to current manufacturing processes using E. coli, Yeast, and Mammalian cells: 47%, 43%, 54% of cost reduction relatively.




02

Reduced time required for product development and manufacturing

10x quicker production time compared to mammalian cells




03

Improved protein effectiveness

Optimized effectiveness using pentamer (CTB), nanoparticles (ferritin), and self-assembling nanostructures

About Technology

ChaperNova™ is a protein engineering platform which solves the problem of insoluble aggregate formation

ChaperNova™ is a protein engineering platform based on RNA-protein interaction, addressing the main problem of microbe-based protein manufacturing processes: the formation of insoluble aggregates (Inclusion body).

Our technology removes aggregation by encouraging interaction with RNA during the initial steps of protein synthesis and aims to convert the proteins already expressed in an encapsulated form into their soluble form. Soluble expression improvement and functional constancy have been confirmed through various experiments, most significantly verifying RNA’s dependable combination ability, securing technological confidence.

Technology Overview

ChaperNova™ takes a novel approach by guiding protein folding during early translation, rather than after full formation.

Our Mechanism

Vaxdigm presents a unique, highly-employable protein manufacturing technology based on ChaperNova™

All protein-based products (pharmaceuticals, cosmetics, materials) require an expression system: E.coli, yeast, mammalian cells.

Microbe-expression systems allow low-cost, high-speed production,

yet are limited by protein aggregates.

* M : Marker / Tot : Total protein / Sol : Soluble protein / Insol : Insoluble protein

mobile background

Our Technology ChaperNova™

Biomaterials with quicker productivity,

higher profitability, and improved effectivity.

Ablility to develop multiple pipelines based on the same platform




01

Reduced production costs of protein products

Compared to current manufacturing processes using E. coli, Yeast, and Mammalian cells: 47%, 43%, 54% of cost reduction relatively.




02

Reduced time required for product development and manufacturing

10x quicker production time compared to mammalian cells





03

Improved protein effectiveness

Optimized effectiveness using pentamer (CTB), nanoparticles (ferritin), and self-assembling nanostructures


Vaxdigm Co., Ltd.

CEO Sung Jae Kim

TEL 02-6205-2550

EMAIL hydrogold@vaxdigm.com

BUSINESS NUMBER 657-87-02464

ADDRESS 412ho, 201, Songpa-daero, Songpa-gu, Seoul, Republic of Korea

PRIVACY POLICYㅣTERMS AND CONDITIONS

COPYRIGHT © 2026 VAXDIGM. ALL RIGHTS RESERVED.


Vaxdigm Co., Ltd. 

CEO Sung Jae Kim

EMAIL hydrogold@vaxdigm.com ㅣ TEL 02-6205-2550

BUSINESS NUMBER 657-87-02464 ㅣ ADDRESS 412ho, 201, Songpa-daero, Sonpa-gu, Seoul, Republic of Korea

PRIVACY POLICYㅣTERMS AND CONDITIONS

COPYRIGHT © 2026 VAXDIGM. ALL RIGHTS RESERVED.